2021
DOI: 10.2147/cmar.s329581
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 31 publications
1
9
0
Order By: Relevance
“…Pre-existing sarcopenia was the only independent poor prognostic factor for OS, LRR, and DM for OCSCC that was never reported in previous studies. Although cancer cachexia is a well-known poor prognostic factor for survival in HNC [52,53], ours is the first study to establish pre-existing sarcopenia as an independent prognostic factor for OCSCC.…”
Section: Discussionmentioning
confidence: 81%
See 1 more Smart Citation
“…Pre-existing sarcopenia was the only independent poor prognostic factor for OS, LRR, and DM for OCSCC that was never reported in previous studies. Although cancer cachexia is a well-known poor prognostic factor for survival in HNC [52,53], ours is the first study to establish pre-existing sarcopenia as an independent prognostic factor for OCSCC.…”
Section: Discussionmentioning
confidence: 81%
“…However, this definition precluded the differentiation of pre-existing sarcopenia from cancer cachexia-related sarcopenia [43]. This renders any results on the effect of sarcopenia unclear [43] and does not affect clinical practice in patients with HNC because cachexia is a well-known poor prognostic factor for OS in HNCs [52,53]. Our study is the first to present a clear definition of pre-existing sarcopenia (diagnosed ≥1 year before the diagnosis of OCSCC) in a homogenous group of patients with the same subtype of HNC (OCSCC) undergoing curative surgery.…”
Section: Discussionmentioning
confidence: 99%
“…A study focusing on clinical impact of cachexia in patients with head and neck cancer undergoing chemoradiotherapy by Hayashi et al. ( 22 ) described that cachexia could play a negative role in all adverse events. Regarding grade 3/4 adverse events, a significant difference in the incidence of anemia, neutropenia, and leukopenia was observed between patients with and without cachexia.…”
Section: Discussionmentioning
confidence: 99%
“…More toxicities, treatment gaps, and postoperative complications 21) analyzed the short-term effect of cachexia on postoperative complications, and have reported that adverse events tended to occur in 64.3% of patients with cachexia, a rate that was significantly higher than that in those without cachexia. A study focusing on clinical impact of cachexia in patients with head and neck cancer undergoing chemoradiotherapy by Hayashi et al (22) described that cachexia could play a negative role in all adverse events. Regarding grade 3/4 adverse events, a significant difference in the incidence of anemia, neutropenia, and leukopenia was observed between patients with and without cachexia.…”
Section: Discussionmentioning
confidence: 99%
“…Hayashi et al. ( 23 ) enrolled 192 patients receiving chemoradiotherapy for head and neck cancer, and found that in a setting of chemoradiotherapy, all adverse events were strongly associated with cachexia. Among grade 3–4 adverse events, the frequency of leukopenia, anemia, and neutropenia had significant differences between patients with and without cachexia.…”
Section: Discussionmentioning
confidence: 99%